Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

Camille Chauvin; Laurine Levillayer; Mathilde Roumier; Hubert Nielly; Claude Roth; Anupama Karnam; Srinivasa Reddy Bonam; Anne Bourgarit; Clément Dubost; Aurore Bousquet; Sébastien Le Burel; Raphaële Mestiri; Damien Sene; Joris Galland; Marc Vasse; Matthieu Groh; Mathilde Le Marchand; Camille Vassord-Dang; Jean François Gautier; Nhan Pham-Thi; Christiane Verny; Bruno Pitard; Cyril Planchais; Hugo Mouquet; Richard Paul; Etienne Simon-Loriere; Jagadeesh Bayry; Laurent Gilardin; Anavaj Sakuntabhai

doi:10.1016/j.isci.2023.106124

Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

Camille Chauvin
, Laurine Levillayer
, Mathilde Roumier
, Hubert Nielly
, Claude Roth
, Anupama Karnam
, Srinivasa Reddy Bonam
, Anne Bourgarit
, Clément Dubost
, Aurore Bousquet
, Sébastien Le Burel
, Raphaële Mestiri
, Damien Sene
, Joris Galland
, Marc Vasse
, Matthieu Groh
, Mathilde Le Marchand
, Camille Vassord-Dang
, Jean François Gautier
, Nhan Pham-Thi

Christiane Verny, Bruno Pitard, Cyril Planchais, Hugo Mouquet, Richard Paul, Etienne Simon-Loriere, Jagadeesh Bayry, Laurent Gilardin, Anavaj Sakuntabhai

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens.

Original language	English (US)
Article number	106124
Journal	iScience
Volume	26
Issue number	3
DOIs	https://doi.org/10.1016/j.isci.2023.106124
State	Published - Mar 17 2023
Externally published	Yes

Keywords

Health sciences
Immunology
Virology
treatment

ASJC Scopus subject areas

General

Access to Document

10.1016/j.isci.2023.106124

Cite this

Chauvin, C., Levillayer, L., Roumier, M., Nielly, H., Roth, C., Karnam, A., Bonam, S. R., Bourgarit, A., Dubost, C., Bousquet, A., Le Burel, S., Mestiri, R., Sene, D., Galland, J., Vasse, M., Groh, M., Le Marchand, M., Vassord-Dang, C., Gautier, J. F., ... Sakuntabhai, A. (2023). Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. iScience, 26(3), Article 106124. https://doi.org/10.1016/j.isci.2023.106124

Chauvin, C, Levillayer, L, Roumier, M, Nielly, H, Roth, C, Karnam, A, Bonam, SR, Bourgarit, A, Dubost, C, Bousquet, A, Le Burel, S, Mestiri, R, Sene, D, Galland, J, Vasse, M, Groh, M, Le Marchand, M, Vassord-Dang, C, Gautier, JF, Pham-Thi, N, Verny, C, Pitard, B, Planchais, C, Mouquet, H, Paul, R, Simon-Loriere, E, Bayry, J, Gilardin, L & Sakuntabhai, A 2023, 'Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants', iScience, vol. 26, no. 3, 106124. https://doi.org/10.1016/j.isci.2023.106124

@article{31b08af9ff2043ebbce88f7ce1de4457,

title = "Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants",

abstract = "Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens.",

keywords = "Health sciences, Immunology, Virology, treatment",

author = "Camille Chauvin and Laurine Levillayer and Mathilde Roumier and Hubert Nielly and Claude Roth and Anupama Karnam and Bonam, \{Srinivasa Reddy\} and Anne Bourgarit and Cl{\'e}ment Dubost and Aurore Bousquet and \{Le Burel\}, S{\'e}bastien and Rapha{\"e}le Mestiri and Damien Sene and Joris Galland and Marc Vasse and Matthieu Groh and \{Le Marchand\}, Mathilde and Camille Vassord-Dang and Gautier, \{Jean Fran{\c c}ois\} and Nhan Pham-Thi and Christiane Verny and Bruno Pitard and Cyril Planchais and Hugo Mouquet and Richard Paul and Etienne Simon-Loriere and Jagadeesh Bayry and Laurent Gilardin and Anavaj Sakuntabhai",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = mar,

day = "17",

doi = "10.1016/j.isci.2023.106124",

language = "English (US)",

volume = "26",

journal = "iScience",

issn = "2589-0042",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

AU - Chauvin, Camille

AU - Levillayer, Laurine

AU - Roumier, Mathilde

AU - Nielly, Hubert

AU - Roth, Claude

AU - Karnam, Anupama

AU - Bonam, Srinivasa Reddy

AU - Bourgarit, Anne

AU - Dubost, Clément

AU - Bousquet, Aurore

AU - Le Burel, Sébastien

AU - Mestiri, Raphaële

AU - Sene, Damien

AU - Galland, Joris

AU - Vasse, Marc

AU - Groh, Matthieu

AU - Le Marchand, Mathilde

AU - Vassord-Dang, Camille

AU - Gautier, Jean François

AU - Pham-Thi, Nhan

AU - Verny, Christiane

AU - Pitard, Bruno

AU - Planchais, Cyril

AU - Mouquet, Hugo

AU - Paul, Richard

AU - Simon-Loriere, Etienne

AU - Bayry, Jagadeesh

AU - Gilardin, Laurent

AU - Sakuntabhai, Anavaj

PY - 2023/3/17

Y1 - 2023/3/17

N2 - Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens.

AB - Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens.

KW - Health sciences

KW - Immunology

KW - Virology

KW - treatment

UR - https://www.scopus.com/pages/publications/85147905642

UR - https://www.scopus.com/pages/publications/85147905642#tab=citedBy

U2 - 10.1016/j.isci.2023.106124

DO - 10.1016/j.isci.2023.106124

M3 - Article

C2 - 36776936

AN - SCOPUS:85147905642

SN - 2589-0042

VL - 26

JO - iScience

JF - iScience

IS - 3

M1 - 106124

ER -

Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this